HDHui Deng

Hui Deng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hui Deng has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Changli Wang

    Key Laboratory of Basicand New Drug Research of Traditional Chinese Medicine, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China; Shaanxi University Engineering Research Center of Chinese Medicine Aromatic Industry, Xianyang 712000, Shaanxi, China

    1 shared publication
  • Linjuan Dong

    College of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, Shaanxi 712046, China

    1 shared publication
  • Shiyu Liu

    College of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, Shaanxi 712046, China

    1 shared publication
  • Xiao Song

    School of Pharmacy Shaanxi University of Chinese Medicine Xianyang China

    1 shared publication
  • Xihui Bai

    College of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, Shaanxi 712046, China

    1 shared publication

Latest Publications

  • Open Access

    A Novel Microspheres Formulation of Puerarin: Pharmacokinetics Study and In Vivo Pharmacodynamics Evaluations

    by Xiao Song, Xihui Bai, Shiyu Liu, Linjuan Dong, Hui Deng, Changli Wang

    The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of puerarin loaded carboxymethyl chitosan microspheres (Pue‐CCMs). The differences in pharmacokinetics parameters of rats after intragastric administration of Pue‐CCMs and puerarin were investigated using HPLC. To assess the protective effect of Pue‐CCMs on myocardial injury in rats, serum levels of creatine kinase (CK), lactate dehydrogenase (LDH), total superoxide dismutase (T‐SOD), and malondialdehyde (MDA) were measured, in addition to pathological examinations and immunohistochemical staining. Our present study has shown that the AUC0–t, Cmax, Tmax, MRT0–t of Pue‐CCMs, and puerarin were 20.176 mg·h/L, 3.778 μg/mL, 1 h, 4.634 h and 9.474 mg·h/L, 2.618 μg/mL, 0.542 h, and 3.241 h, respectively. Pue‐CCMs alleviated myocardial ischemic injury. Pretreatment with Pue‐CCMs could significantly decrease CK, LDH, and MDA levels and increase T‐SOD level in the serum. Pue‐CCMs downregulated expression of the Bcl‐2 associated X protein (Bax) and upregulated B‐cell lymphoma‐2 (Bcl‐2) expression. Compared with puerarin group, the Pue‐CCMs group could improve the oral bioavailability of puerarin. The protective effect of Pue‐CCMs against myocardial injury was significantly greater than puerarin at the same dose. In summary, Pue‐CCMs should be a qualified and promising candidate as a new oral preparation of puerarin.